Bicycle Therapeutics plc (BCYC) Stock

About Bicycle Therapeutics plc

Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leading investigational product, BT1718, is a Bicycle Toxin Conjugate (BTC) that is undergoing Phase I/IIa clinical trials. This candidate is engineered to target tumors specifically expressing Membrane Type 1 matrix metalloprotease. Other oncology assets in their pipeline include BT5528, also a BTC in Phase I/II studies, which targets EphA2, and BT8009, currently in Phase I/II clinical development, designed to target Nectin-4. Beyond cancer, Bicycle Therapeutics is advancing THR-149, a plasma kallikrein inhibitor that has completed Phase II clinical trials for the treatment of diabetic macular edema. Their portfolio also includes Bicycle tumor-targeted immune cell agonists (TICAs) such as BT7480, which targets Nectin-4, and BT7455, an EphA2/CD137 TICA presently in preclinical development. The company actively fosters collaborations with various biopharmaceutical entities and organizations, broadening its development efforts into therapeutic areas like anti-infectives, cardiovascular conditions, ophthalmology, and respiratory illnesses. Notable partnerships include a clinical trial and license agreement with Cancer Research Technology Limited and Cancer Research UK. They also maintain research collaborations with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund. Furthermore, a significant discovery collaboration and license agreement with Genentech is in place for the identification and development of Bicycle peptides for multiple immuno-oncology targets.

Bicycle Therapeutics plc is headquartered in GB.

Bicycle Therapeutics plc (BCYC) stock trades at $4.22 with a market capitalization of $292.84M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.34, reflecting a net loss over the last twelve months, price-to-book of 0.53, price-to-sales of 4.61. Over the past 52 weeks the stock has ranged between $3.92 and $9.18, and currently trades 54.0% below its 52-week high.

On profitability, Bicycle Therapeutics plc generates a return on equity (ROE) of -35.74% (negative, reflecting a net loss), return on capital employed of -40.17%, an operating margin of -381.75%, a net profit margin of -344.95%.

Official website: www.bicycletherapeutics.com

Bicycle Therapeutics plc by the numbers, 2016–2025

Between 2016 and 2025 Bicycle Therapeutics plc reported revenue of $0 rising to $73.0M. Compounded, revenue has grown 48.8% a year over five years, 73.4% over three, 108.6% over the last twelve months. Net profit fell to $-219.0M.

The most recent net margin is -344.95%. On a trailing twelve-month basis to Mar '26, revenue is $64.0M and net profit $-219.0M.

Borrowings stand at $18.0M, cash on hand is $559.5M, cash from operations was $-250.0M in the latest year, positive in 0 of the last 10.

Return on equity has averaged -33.4% over five years, and was -35.9% in the most recent year.

The share price itself has compounded at -34.1% a year over five years, -45.6% over three, -45.0% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Bicycle Therapeutics plc (BCYC) — frequently asked questions